Overview
In January 2022, the European Union introduced a new Clinical Trials Regulation (CTR), repealing the earlier Directive 2001/20/EC, or CT Directive (CTD). The new EU-CTR regulation aims to harmonize the process of assessment and supervision of clinical trials throughout the EU. All Pharma companies operating in the EU must comply with EU-CTR for all new trials. Each submission requires careful identification of country-specific documents, and a workflow cycle that spans creation through approval.
Challenges with the Submissions Process:
Key Features & Functionality